Key result
Transcatheter pulmonic valve implantation has emerged as a comparable alternative to surgical pulmonic valve replacement, demonstrating favorable medium-term outcomes and low procedural mortality.
Why the study?
Surgical pulmonic valve replacement has been the standard of care for RVOT dysfunction, but transcatheter pulmonic valve implantation has emerged as a comparable alternative requiring comprehensive review.
Does transcatheter pulmonic valve implantation provide comparable outcomes to surgical pulmonic valve replacement in patients with RVOT residual abnormalities?
Does transcatheter pulmonic valve implantation provide comparable outcomes to surgical pulmonic valve replacement in patients with RVOT residual abnormalities?
Transcatheter pulmonic valve implantation is a comparable alternative to surgical pulmonic valve replacement with favorable medium-term outcomes and low complication rates for patients with RVOT dysfunction.
Supports selected use as a less-invasive alternative; leaves open long-term SPVR comparison, endocarditis risk, and native-RVOT durability.
After surgical repair, these patients develop RVOT residual abnormalities of pulmonic stenosis and/or insufficiency of their native outflow tract or right ventricle to pulmonary artery conduit. There are also sequelae of other surgeries like the Ross operation for aortic valve disease that lead to right ventricle to pulmonary artery conduit dysfunction. Surgical pulmonic valve replacement (SPVR) has been the mainstay for these patients and is considered standard of care. Transcatheter pulmonic valve implantation (TPVI) was first reported in 2000 and has made strides as a comparable alternative to SPVR, being approved in the United States in 2010. We provide a comprehensive review in this space-indications for TPVI, detailed procedural facets and up-to-date review of the literature regarding outcomes of TPVI. TPVI has been shown to have favorable medium-term outcomes free of re-interventions especially after the adoption of the practice of pre-stenting the RVOT. Procedural mortality and complications are uncommon. With more experience, recognition of risk of dreaded outcomes like coronary compression has improved. Also, conduit rupture is increasingly being managed with transcatheter tools. Questions over endocarditis risk still prevail in the TPVI population. Head-to-head comparisons to SPVR are still limited but available data suggests equivalence. We also discuss newer valve technologies that have limited data currently and may have more applicability for treatment of native dysfunctional RVOT substrates.
No takes yet. Share an insight, caveat, or question.
Law et al. (2021) conducted a review in Right ventricular outflow tract (RVOT) obstruction and pulmonary valve disease. Transcatheter pulmonic valve implantation (TPVI) vs. Surgical pulmonic valve replacement (SPVR) was evaluated. Transcatheter pulmonic valve implantation has emerged as a comparable alternative to surgical pulmonic valve replacement, demonstrating favorable medium-term outcomes and low procedural mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: